Uxogyn Presents New Data Showing The Ability Of Eeva™ To Non-Invasively Predict Embryo Advancement With Increased Accuracy

Date: Jul-07-2012Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, has presented data showing the ability of its flagship product, the Early Embryo Viability Assessment (Eeva) Test, to predict embryo advancement with a new level of accuracy. The Eeva™ Test uses intelligent computer vision software to measure key parameters from video images and predicts with high accuracy at the cleavage stage which embryos will likely grow to the blastocyst stage. These clinical data were presented at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting in Istanbul, Turkey.

In a prospective multi-center cohort study of 160 patients and close to 1,800 embryos, the Eeva
Test was able to predict blastocyst formation at the cleavage stage with 85 percent specificity,
reducing the false positive rate from 43 percent to 15 percent compared with traditional
morphology selection. Eeva also demonstrated the ability to track and analyze cell division
timings with greater than 90 percent accuracy. Additionally, Eeva was able to increase the
consistency of embryo assessment across embryologists.

"Remarkably, we found that Eeva may in fact improve embryo selection for cleavage-stage
transfer," said David Adamson, M.D., adjunct clinical professor at Stanford University, associate
clinical professor at UCSF, director of Fertility Physicians of Northern California and principal
investigator of the Eeva study. "Eeva provided early insights that we expect will prove to be
valuable for cycle consultation and planning of future treatment with our patients. The ability to
predict with an increased degree of accuracy appears to be outstanding and will change the
way we care for our IVF patients."

"We are delighted that these study results both confirm the groundbreaking discovery published
by Stanford University in Nature Biotechnology and demonstrate the clinical value that Eeva
provides to reproductive specialists and their patients," said Lissa Goldenstein, president and
chief executive officer of Auxogyn. "These data, which we included in both our CE and FDA
regulatory filings, represent significant progress in our commitment to the rigorous study and
validation of our technology, which we believe is essential in the IVF field."

"Given our progress to date, we expect to receive CE clearance for Eeva in the EU imminently,"
added Ms. Goldenstein. "We are also on track to submit our 510(k) filing to the FDA this month."

About IVF

Infertility affects one of every six couples, but little or no new scientific and clinical
breakthroughs in reproductive health have occurred in decades. The demand for assisted
reproduction tools and procedures is growing by approximately 10 percent per year due to
higher infertility rates caused by an increasing maternal age as more women are starting
families later in life. The demand is growing despite the fact that, in the U.S., the cost per cycle
is between $13,000 and $15,000, and only one-third of cycles result in a live birth. This
necessitates the transfer of multiple embryos and/or conducting multiple cycles, leading to
greater physical, emotional, practical and financial costs, before determining if pregnancy can
be achieved.

About the Eeva™ Test

Auxogyn's non-invasive, Early Embryo Viability Assessment (Eeva) Test is designed to improve
IVF outcomes by providing clinicians and patients with objective information that will enable
them to more confidently select embryo(s) for transfer. Eeva's proprietary software automatically
analyzes embryo development against scientifically and clinically validated cell-division
parameters. With Eeva's quantitative data for each embryo's potential development, IVF clinics
may be able to optimize the treatment path for their patients undergoing IVF procedures. Eeva
is limited by United States law to investigational use and is under clinical investigation in the
European Union.

Courtesy: Medical News Today Note: Any medical information available in this news section is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional.